Physician profile
Prem Soman
NPI 1265407225
$38,835.69
in general payments reported to CMS, 2019-2025
6 companies · $21K in 2025
The $21K reported for 2025 was more than what 96% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,030 · 2020: $7,055 · 2021: $20.24 · 2022: $101 · 2023: $2,903 · 2024: $2,911 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,672 · Travel and Lodging: $2,318 · Food and Beverage: $343 · Education: $51.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,245.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,671.71 |
| Travel and Lodging | $2,318.10 |
| Food and Beverage | $342.60 |
| Education | $51.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27,805.62 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $10,946.74 | 2020-2025 | Onpattro, Amvuttra |
| Life Molecular Imaging Ltd | $83.33 | 2023 | Neuraceq |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prem Soman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.